Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00588198 · ClinicalTrials.gov registry record
Peripheral Blood and/or Bone Marrow, Including Detection of Occult Metastases, in Patients With Melanoma
A clinical trial of Melanoma, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- 754
- Enrollment target
- 1
- Study location
NCT00588198: Completed study of Melanoma, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00588198 is a study of Melanoma that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 754 participants, roughly in line with the 704-participant average among 266 other Melanoma trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00588198, a study of Melanoma, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- 754 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine if tumor cells can be detected in the peripheral blood and/or bone marrow of patients with melanoma.
Conditions Studied
Study Locations (1)
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 754 participants |
| Start Date | 1991-10 |
| Est. Completion | 2009-09 |
What the finished NCT00588198 record still lists
NCT00588198 is an observational study that tracks outcomes without assigning an intervention. The registered 754 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 704-participant average among 266 other Melanoma trials with a reported enrollment target.
The record links to 1 condition, with Melanoma appearing as the primary indexed condition, and to 0 interventions.
NCT00588198 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT00588198 about?
NCT00588198 is a clinical study titled "Peripheral Blood and/or Bone Marrow, Including Detection of Occult Metastases, in Patients With Melanoma". The purpose of this study is to determine if tumor cells can be detected in the peripheral blood and/or bone marrow of patients with melanoma.
What is the current status of trial NCT00588198?
This trial is currently completed. The enrollment target is 754 participants. The study started on 1991-10. Estimated completion is 2009-09.
What conditions does trial NCT00588198 study?
This clinical trial studies the following conditions: Melanoma.
Who is sponsoring clinical trial NCT00588198?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00588198 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00588198's enrollment target sits among peer trials
754 29th of 266 higher than 238 of 266 other Melanoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Melanoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer or Melanoma
RECRUITING · NA
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
Dabrafenib and/or Trametinib Rollover Study
RECRUITING · Phase 4
-
Neoadjuvant Immune Checkpoint Blockade + a Prebiotic Food-enriched Dietary Intervention to Optimize Immune Response in Melanoma: NEO-PreFED
RECRUITING · Phase 2
-
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
RECRUITING · Phase 1
-
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05379985 · 754 participants · Phase 1
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
- NCT05427370 · 754 participants · NA
The Canadian CABG or PCI in Patients With Ischemic Cardiomyopathy Trial (STICH3C)
- NCT05869149 · 756 participants · NA
Systems Science Approaches to Improve Access to Healthier Foods: The FRESH Trial
- NCT06095583 · 756 participants · Phase 3
Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia